Investors
Company Profile
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
Financial Reports
Investor presentations
SVB Leerink Presentation Feb 24, 2021
Corporate Deck February 2021
Corporate Deck January 2021
JPM Presentation Jan 14, 2021
Investor Deck December 2020
Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids
Investor Presentation Jefferies Virtual London Healthcare Conference November 18, 2020
Results: PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
Press Releases
ObsEva appoints David Renas as Chief Financial Officer
press release
January 4, 2021
Geneva, Switzerland and Boston, MA – January 4, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…
Read moreObsEva Announces Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids
press release
December 10, 2020
PRIMROSE 1 52-week results confirm the sustained efficacy and continued safety of linzagolix (Yselty®), with a potential best-in-class high-dose option…
Read moreObsEva SA to present at The International Society of Gynecological Endocrinology 19th World Congress – virtual edition, December 2-5, 2020
press release
December 1, 2020
Geneva, Switzerland and Boston, MA – December 1, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…
Read moreGeneral Meetings
ObsEva Annual General Meeting 2020
June 9, 2020
ObsEva Annual General Meeting 2019
May 8, 2019
Upcoming Events
Stock Information
Latest Press Release
ObsEva to Present at the SVB Leerink 10th Annual Global Healthcare Conference
Geneva, Switzerland and Boston, MA – February 17, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…
Read moreInvestor Contact
Media Contact
Media Switzerland & Europe
Shauna Dillon
+41 (0)22 552 1550 Office
+41 79 360 3533 Mobile
Media United States
Shauna Dillon
+41 (0)22 552 1550 Office
+41 (0)79 360 3533 Mobile
Contacts
ObsEva Switzerland Office
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840
Media Switzerland & Europe
Shauna Dillon
+41 (0)22 552 1550 Office
+41 79 360 3533 Mobile
Media United States
Shauna Dillon
+41 (0)22 552 1550 Office
+41 (0)79 360 3533 Mobile
Sign up for news
